应用微小残留病灶检测优化 AML、ALL 和慢性髓性白血病的管理。
Using Measurable Residual Disease to Optimize Management of AML, ALL, and Chronic Myeloid Leukemia.
机构信息
Department of Medicine, Oregon Health & Science University, Portland, OR.
France Intergroupe des Leucémies Myéloïdes chroniques FiLMC, Hôpital Saint-Louis APHP, Paris, France.
出版信息
Am Soc Clin Oncol Educ Book. 2023 Jun;43:e390010. doi: 10.1200/EDBK_390010.
In this review, we discuss the use of measurable residual disease (MRD) in AML, ALL, and chronic myeloid leukemia (CML). Our aims were to review the different methodologies for MRD assessment; describe the clinical relevance and medical decision making on the basis of MRD; compare and contrast the usage of MRD across AML, ALL, and CML; and discuss what patients need to know about MRD as it relates to their disease status and treatment. Finally, we discuss ongoing challenges and future directions with the goal of optimizing MRD usage in leukemia management.
在这篇综述中，我们讨论了可测量残留病（MRD）在急性髓系白血病（AML）、急性淋巴细胞白血病（ALL）和慢性髓性白血病（CML）中的应用。我们的目的是回顾评估 MRD 的不同方法；根据 MRD 描述其临床相关性和医学决策；比较和对比 AML、ALL 和 CML 中 MRD 的使用；并讨论患者需要了解的与疾病状态和治疗相关的 MRD 信息。最后，我们讨论了当前的挑战和未来的方向，旨在优化白血病管理中 MRD 的使用。
Zotero 插件